ProtoKinetix' AAGP™ Proves to be a Powerful Additive

PROTOKINETIX INC. (PKTX: OTCBB)
VANCOUVER, BRITISH COLUMBIA, JANUARY 26, 2006

ProtoKinetix, Inc. (PKTX), announces today that in addition to AAGP™’s ability to preserve and maintain the viability of skin cells, it has proven to be a strong additive with other protective agents. ProteoCell Laboratories have just completed a series of tests comparing AAGP™ to Co-enzyme Q10 (a strong anti-oxidant) as well as in combination with it. Co-enzyme Q10 (CoQ10) is a vitamin-like substrate found in almost every cell of the body. CoQ10 acts as a potent anti-oxidant that protects tissues and organs from oxidative damage.

Previous results have demonstrated AAGP™ protective activity against hydrogen peroxide (H2O2) and ultraviolet radiation (UV-C) is present and strong even at low concentrations. The results of the side by side comparisons to CoQ10 and in combination with this anti-oxidant are as follows:

After 48-hours at body core temperature (37°C), the untreated adult skin cells exposed to H2O2 had a 10% survival rate. Cells treated with a low dose of AAGP™ had a 30% survival rate as opposed to only an 18% survival rate on cells treated with the maximum concentration of CoQ10. However, using a very low concentration of 5mg/ml of AAGP™ and the maximum possible concentration of CoQ10, the cell survivability of H2O2 exposed skin cells was 48%. Using adult skin cells exposed to UV-C radiation after 48-hours at 37°C, the untreated cells had a 5% survival rate. The AAGP™ treated cells had a 60% survival rate using only 5mg/ml as opposed to only 12% survival rate of cells treated with CoQ10.

Using the above concentrations, the cell survivability of UV-C exposed skin cells treated with AAGP™ and CoQ10 was 77%.

These dramatic results have opened up many additional potential applications for this amazing family of AAGP™ molecules.

About ProtoKinetix:

ProtoKinetix Inc. is a scientific development company whose mission is the advancement of human health care. The Company’s first entry into the commercial market place will be the launch of the first synthetic age-arresting glycoprotein (AAGP™). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development in the areas of cell, tissue and organ preservation.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,

Dr. John Todd, President

Company Office:                       
Suite # 1500           
885 West Georgia Street           
Vancouver, BC  V6C 3E8          

Investor Contact:
BCGU, Business Consulting Group Unlimited
In the U.S.:  (888) 772-1288
Outside the U.S.: (760) 230.2300 ext 206